Compare TEI & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEI | XFOR |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 318.6M |
| IPO Year | N/A | 2017 |
| Metric | TEI | XFOR |
|---|---|---|
| Price | $5.72 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 172.1K | ★ 739.5K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $5.75 | $2.43 |
| 52 Week High | $7.00 | $4.83 |
| Indicator | TEI | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 26.33 | 45.77 |
| Support Level | N/A | $2.86 |
| Resistance Level | $6.81 | $4.49 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.89 | 32.61 |
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.